The Promise Of Cell Technologies In Immunotherapy

by Irina Bilous    Contributor 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   3367    Comments 0

The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some cancers. Cell technologies, as a growing sub-field in the immunotherapy landscape, have progressed considerably and now represent a $26 billion financial opportunity by 2030, according to a report by Roots Analysis.

Evolutionarily, the immune system has adapted to distinguish between foreign or tumor antigens and the body's own cells. To prevent autoimmune reaction, T-lymphocytes carry on special PD-1 (programmed cell death-1) receptor, that verify foes before attacking them. Insidious cancer cells often express a ligand to this receptor - PD-L1, triggering intracellular mechanisms that block T-cells response. Inhibitors for this PD-1/PD-L1 and other checkpoint pathways (Opdivo, Keytruda, Yervoy) are being routinely used.

Thanks to the success of checkpoint therapies, immunotherapy ramped up its popularity, shifting toward the development of cell therapies. The Car T-cells have shown success in treating blood cancers in patients who have not responded to almost any of available treatments. Car T-cells are engineered to express Chimeric Antigen Receptors with a high affinity to tumors antigens. Despite groundbreaking results, the technology has its own limitations and required significant improvements. 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Industry Trends    Novel Therapeutics   

Share this:              

You may also be interested to read:

 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *